- Delcath Systems (NASDAQ:DCTH +45.6%) rallies on almost a 9x surge in volume in response to a retrospective analysis of 49 ocular melanoma patients treated during an eight-year period at two cancer centers that showed a treatment effect in those whose cancer had metastasized in the liver and underwent percutaneous hepatic perfusion (PHP) using Melphalan/HDS. The results were presented at the Regional Cancer Therapies 12th International Symposium in Snowbird, UT.
- The data showed 45.7% of the above patients experienced a partial or complete response. The study also showed that overall survival of responders was projected to be more than three years. A total of 115 PHP treatments were administered (median = 2).
- Delcath's PHP therapy delivers a high dose of melphalan, a chemotherapeutic agent, directly to the liver via a catheter over a period of 30 minutes.